Fortis Healthcare has reported a total income of Rs.1,418.15 crores during the period ended June 30, 2021, as compared to Rs.610.40 crores for the corresponding period last fiscal. For the period ended March 31, 2021, the total income stood at Rs 1,258.78 crores.

The company has posted a net profit of Rs.263.55 crores for the period ended June 30, 2021, as against a loss of Rs 178.92 crores for the corresponding fiscal last year. For the period ended March 31, 2021, the company reported a net profit of Rs 43.17 crores.

Commenting on the results for the quarter, Dr Ashutosh Raghuvanshi, MD and CEO, Fortis Healthcare stated, “Our efforts and the resilience of our workforce has enabled us to respond to the second wave as effectively as possible and simultaneously ensure that our core business remains on track. Month on month non-covid occupancy improved from 30% in May to approx. 47% in June. We expect the momentum to continue allowing the business to return to near normal in the short term. We are also progressing well on our strategic initiatives and have also initiated investments for advanced medical equipment such as Cath Labs, neuro microscopes, bone marrow transplant units and the likes in select facilities. The diagnostics business I believe is now well-positioned for accelerating its growth and profitability. At the same time, we cannot discount the possibility of a third wave which could impact operations in future. However, having augmented our resources both on the clinical and non-clinical fronts, we are relatively better prepared for such eventualities. FY22 has seen a challenging start but business has recovered well and I expect to see progressively better quarters going forward.”

 The company has reported EPS of Rs.3.49 for the period ended June 30, 2021, as compared to Rs (2.37) for the corresponding period last fiscal. The EPS for the period ended March 31, 2021, stood at Rs 0.57.